Kidney Disease in Type 2 Diabetes: Disease Progression and Emerging Therapies
CME 2011 (Satellite Symposium)
June 26, 2011 - San Diego, CA
HDCN free zone registration is required. If you don't already have one,
click here to register and get an HDCN username and password.
Welcome and Introductory Remarks
Philip Raskin, MD
Pathogenesis of Chronic Kidney Disease in Type 2 Diabetes
Jennifer B. Marks, MD

Current Guidelines and Therapeutic Options for Treatment of CKD in Type 2 Diabetes
Jerry Yee, MD

Emerging Therapies and Future Management of CKD in Type 2 Diabetes
Mark Molitch, MD

Panel Discussion
Drs. Marks, Yee, and Molitch

Philip Raskin, MD
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Jennifer B. Marks, MD
Professor of Internal Medicine
University of Miami Miller School of Medicine
Director, Diabetes Management Program, Miami VAMC
Miami, Florida

Jerry Yee, MD
Division Head, Nephrology and Hypertension
Henry Ford Hospital
Detroit, Michigan

Mark Molitch, MD
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Physicians click on the blue button to obtain CME credit.

Other health care professionals, please click on the orange button to obtain a certificate of completion.
This educational activity is an audio recording with accompanying slides of a live presentation held June 26, 2011, in San Diego, CA. Continuing medical education credit will be awarded to physicians who successfully complete this activity with a score of 75% or better on the post-test and return an evaluation. Participation should take approximately 1.5 hours.

To complete this activity and receive credit, the participant should listen to the talks, scroll down to review the accompanying slides, review the PubMed abstracts of the linked slides and references, complete the post-test and evaluation, and read the abstracts linked to the post-test feedback section.

Release Date: October 15, 2011
Review/Approval Date: October 15, 2011
Expiration Date: October 15, 2012
AMA PRA Category 1 Credits™: 1.5

To complete this educational activity, the user will need Windows (XP or higher) or Macintosh (version 9.0 or higher) operating software, a connection to the internet with a 28.8 kbps MODEM or better. The computer should have an audio card with speakers. An audio player, either the Windows Media Player (downloadable from the Real Player from Real Media ( is required and either can be downloaded for free per instructions on the individual lecture pages. Flash 8.0 (from is required to see the full-screen slide/audio presentations and the video presentations. Acrobat Reader is required to print the CME certificate, and this can be download free from

For questions regarding CME credit, the post-test, or evaluation, please call Southwestern Medical Center continuing Education at (214) 648-2166 or e-mail
This educational activity was supported by an educational grant from Reata Pharmaceuticals.

Program Overview
This program will provide an overview of the progression of Chronic Kidney Disease in Type 2 Diabetes. Topics will include: the pathogenesis of Chronic Kidney Disease in Type 2 Diabetes; current guidelines and therapeutic options for the treatment and management of CKD in Type 2 Diabetes; and emerging therapies and future management of CKD in Type 2 Diabetes.

Learning Objectives
At the conclusion of this program, participants will be able to:
  • Describe the pathogenesis of CKD in Type 2 Diabetes
  • Identify the current guidelines for managing CKD
  • Evaluate current therapeutic options for the treatment of CKD in Type 2 Diabetes
  • Evaluate future therapies and management options for the treatment of CKD in Type 2 Diabetes
Target Audience
This CME symposium is intended for endocrinologists, nephrologists, general internal medicine

Accreditation Statement
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
The University of Texas Southwestern Medical Center designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of the Office of Continuing Medical Education at The University of Texas Southwestern Medical Center to ensure balance, independence, objectivity, and scientific rigor in all CME activities. It is also our policy that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Each speaker and planner has completed and signed a conflict of interest form that is summarized below. Information and opinion offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information. Because this course is meant to educate clinicians on what is currently in use and what may be available in the future, there may be discussion of “off-label” uses. Speakers have been requested to inform the audience when off-label uses are being discussed.

Philip Raskin, MD
Research Support: Aegera Therapeutics, Bayhill Therapeutics Inc., Biodel Inc., Boehringer Ingelheim Pharmaceuticals Inc., Calibra Medical Inc.,
Advisor: Amgen, AstraZeneca, Novo Nordisk Inc., MannKind Corporation, Quigley Pharma Inc.
Speaker’s Bureau: Merck & Co. Inc., Novo Nordisk Inc
Jennifer Marks, MD
Research Support: Macrogenics, Amylin, Roche/Genentech, Lilly, Mannkind
Advisor: Macrogenics, Roche/Genetech
Jerry Yee, MD
Speaker’s Bureau: Amgen, Takeda, Otsuka
Advisor: Amgen, Affymax, Takeda, Otsuka

Mark Molitch, MD
Research Support: Reata, Sanofi-Aventis, Eli Lilly & Co.
Consultant: Sanofi-Aventis, Abbott Laboratories, Novartis, Ipsen, Corcept

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of. or promotion by, Southwestern Medical Center. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

The content and views presented in this educational program are those of the faculty and do not necessarily reflect those of Reata Pharmaceuticals and Southwestern Medical Center. Before prescribing any medicine, primary references and full prescribing information should be consulted.

Off-label/lnvestigational Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Before prescribing any medication, physicians should consult primary references and full prescribing information. The faculty presenters will disclose if any unlabeled use of products is mentioned in their presentations. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Southwestern Medical Center Privacy Policy
Southwestern Medical Center is committed to on-line privacy and confidentiality. This website is managed by HDCN, and their printed privacy policy applies to this site. CME credit for "Kidney Disease in Type 2 Diabetes: Disease Progression & Emerging Therapies" is provided by The University of Texas Southwestern Medical Center. If you register for CME credit for this educational activity, HDCN will forward relevant personally identifiable information to Southwestern Medical Center so that we can maintain records concerning credits we issue to you. We may share aggregated data concerning registrations, post-tests, and evaluations on request of our joint sponsor (Reata Pharmaceuticals) and/or the commercial supporter. We will not share any personally identifiable information. The University of Texas Southwestern Medical Center may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through The University of Texas Southwestern Medical Center. For more information, contact

The CME policy statements of HDCN are listed on this page.